Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DLX105 in painful knee osteoarthritis
NCT00819572Phase 2Completed
- Sponsor
- ESBATech
- Start
- Dec 2008
- Primary completion
- Sep 2010
- Modality
- Antibody Conjugates, scFv Fragments, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of DLX105 in osteoarthritis (OA) (3 arms), sponsored by ESBATech. Primary endpoints: Visual Analogue Scale for Pain Intensity at Day 7 and Safety and Tolerability Assessment at 12 weeks. Started Dec 2008; status: completed.
02
Drugs
DLX105
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT00819572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00819572.